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ABSTRACT
We conduct studies in an attempt to characterize the patients and outcome of the
Indonesian childhood ALL treatment protocol in our Pediatric Care Unit with the setting of
low-income country. The results showed that the annual incidende rate of acute leukemias
has increased significantly from 35 in 1999 to 70 per-million per-year in 2009 with a
relatively high percentage of the children have AML. Of all ALL cases 83% is B-cell ALL and
17% is T-cell ALL.
Our study concerning response to treatment showed that chemotherapy induced
apoptosis of leukemic cells and patients showing poor early response to treatment were
significantly associated with adverse presentations at diagnosis, higher induction failure and
resistant disease rate with a lower 5-year disease-free survival (DFS) and 5-year event-free
survival (EFS) rate as compared with good responders.
Our randomized trials failed to show the benefit of a) prophylactic oral ciprofloxacin
against sepsis and mortality during induction treatment, b) treatment intensification using
3 additional doses of L-asparaginase during consolidation in preventing relapse and
improving DFS and EFS, c) dexamethasone over prednisone in terms of EFS, DFS and
overall survival. There was a trend of higher induction death rate in standard risk patients
using dexamethasone in the 4-drug induction of Indonesian protocol.
We found that the high rate of treatment abandonment and toxic death were the
major obstacles in our PCU till now that generated a low survival rate. However, the
treatment outcome of childhood ALL in our setting has shown progress with the 3-year EFS
from 23% (1999-2005) to 37% (2006-2011) as the benefit of our twinning program with the
VU University Medical Center, Amsterdam.
